目的：观察抗CD20单抗联合环磷酰胺、长春新碱、阿霉素及泼尼松治疗初诊的弥漫性大B细胞淋巴瘤(DLBL)的临床疗效。方法：2002-04-2003-02， 52例病人进入本研究。化疗采用标准的CHOP方案：环磷酰胺600 mg/m2（第1天），长春新碱1.4 mg/m2（第1天），阿霉素25 mg/m2（第1天）和泼尼松60 mg/d（第1～5天），每3周1个疗程，共6个疗程。利妥昔单抗静脉滴注剂量为375 mg/m2，每周或每3周输注1次，连续4次或6次。结果：在50例患者中，60%获得完全反应(CR)，总有效率(OR)为100%。50例患者共随访了2~30周，患者16周的疾病无进展生存(PFS)率为87.3%。主要不良反应为输注相关的不良反应（32%）和化疗相关的血液学毒副反应（20%）。结论：利妥昔单抗联合CHOP方案可有效用于治疗新诊断的弥漫性大B细胞性淋巴瘤具有较高的缓解率，不良反应较少。

Objective: To evaluate the efficacy of rituximab combined with cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP regimen) in treating the initially diagnosed diffuse large B cell lymphoma (DLBL). Methods: 2002-04-2003-02, 52 patients were enrolled in this study. Chemotherapy was conducted with cyclophosphamide 600 mg·m-2, vincristine 1.4 mg·m-2, docorubicin 25 mg·m-2 on d1 and prednisone 60 mg·d-1 for successive 5 d, every 3 weeks, for 6 courses. Rituximab was given at the dose of 375 mg·m-2 every 1 or 3 weeks, for 4 or 6 courses. Results: In 50 patients who were evaluated for efficacy, complete response rate and overall response rate were achieved at 60% and 100%, respectively. 50 patients were followed-up for 2～30 weeks (mean 8±5) and estimated progress free survival (PFS) rate of 16 weeks was 87%. The regimen could be well tolerated, and the major adverse reactions were infusion-related response (32%) and hematological toxicities (20%).Conclusion: Rituximab in combined with CHOP can be successfully applied to the therapy of initially diagnosed diffuse large B cell lymphoma, with adverse reactions.